Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.47 |
| ▸ | DDT | P30046 | 3/20 | 0.46 |
| ▸ | SCARB1 | Q8WTV0 | 3/20 | 0.42 |
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | LYN | P07948 | 2/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496001 | 0.90 | MAPK14 (0.46) | MAPK14SCARB1BRAFLYNMAPK9 | |
| SCHEMBL4483684 | 0.89 | MAPK14 (0.49) | MAPK14BRAFLYNMAPK9 | |
| SCHEMBL5777792 | 0.89 | MAPK14 (0.46) | MAPK14SCARB1BRAFLYNMAPK9 | |
| SCHEMBL4496075 | 0.88 | MIF (0.47) | MIFMAPK14BRAF | |
| SCHEMBL4494544 | 0.88 | MAPK14 (0.46) | MIFMAPK14DDTSCARB1BRAF | |
| SCHEMBL4498741 | 0.86 | MAPK14 (0.46) | MIFMAPK14DDTSCARB1BRAF | |
| SCHEMBL4507183 | 0.84 | DDT (0.50) | MAPK14DDTBRAF | |
| SCHEMBL5620583 | 0.82 | BRAF (0.46) | MAPK14BRAF | |
| SCHEMBL13757154 | 0.82 | BRAF (0.46) | MAPK14BRAF | |
| SCHEMBL6808232 | 0.82 | BRAF (0.45) | MAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | claimed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | claimed |
| US-7569568-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20070032492-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-7166628-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1567507-B1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | MIF 40/4885MAPK14 1621/4885DDT 4803/4885 |
| US-20070032492-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1RN | MIF 61/4885MAPK14 2079/4885DDT 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.